Skip to main content
| News

University of Basel investigating active substances against the coronavirus

09.03.2020

The University of Basel is using computer-aided methods in its efforts to find an active substance to fight the coronavirus. A total of just under 700 million substances have been tested on a virtual basis. This has allowed interesting substances to be identified already.

Research (Img: FreeImages.com)

The search for an active substance effective against the coronavirus is being advanced by a Computational Pharmacy research group at the Department of Pharmaceutical Sciences of the University of Basel, as detailed in a press release. The research group is being headed up by Markus Lill and has conducted virtual screening, as part of which more than 680 million substances have already been tested on a virtual basis.

The tests are focused on an important enzyme of the coronavirus, namely the central protease. If the virus’s critical enzyme can be inhibited, this can prevent it from further multiplying. A number of “interesting substances” have already been identified. “Even if the complete development of a drug to fight this particular coronavirus is likely to exceed the duration of the current epidemic, it is important to develop drugs for future coronaviruses”, Lill explains in the press release.

The Basel-based research group’s recent work should serve as a foundation. This is also illustrated by the fact that the research group has taken the decision to immediately make “the test results publicly available in the form of an open-source preprint”. The aim of the Basel researchers is therefore to allow other research groups to make use of their proposals and test potential drug candidates themselves. This approach is rooted in the current emergency situation, given that it is otherwise customary for interesting substances to be first experimentally tested together with other research groups before the results are patented and published, the press release states.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

VectivBio sold for approximately 1 billion dollars
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

VectivBio sold for approximately 1 billion dollars

The takeover of VectivBio is now being finalized: the Boston-based firm Ironwood Pharmaceuticals, which specializes in gastrointestinal medicine, has agreed...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

University of Basel and RocketVax present new Covid vaccine

Researchers from the University of Basel have developed a new concept for a Covid vaccine in collaboration with the biotech...

Read More
Advanced Manufacturing/AI, Basel Area Business & Innovation, Innovation, Invest

Rami Swiss and Elbit Systems now manufacturing in Jura

The newly established company Rami Swiss has inaugurated a new production facility in Courtételle in the canton of Jura together...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Basel to become Europe’s Silicon Valley of biotech

Silicon Valley is synonymous with technology and innovation, and home to dozens of Fortune 1000 companies and thousands of startups....

Read More
Roche and Novartis among global leaders for research spending
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Roche and Novartis among global leaders for research spending

In 2022, Roche invested 16 billion euros in research and development overall. This puts the Basel-based life sciences firm in...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Roche to found Institute for Human Biology

Roche has announced that it will be establishing the Institute of Human Biology in Basel. Up to 250 employees will...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Provectis establishes presence in Basel

Provectis Healthcare has chosen Basel as the location for its headquarters. The company is striving to become the partner of...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Alentis raises 105 million US dollars

Alentis Therapeutics has received 105 million US dollars in a series C funding round. It will invest the funds in...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech, Medtech

Spirecut establishes presence in the Basel Area

Spirecut has opted to establish its new headquarters in the canton of Basel-Landschaft. The company is now operating out of...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech, Sustainability

Evolva launches new line for manufacturers of personal care products

Evolva, a manufacturer of active ingredients based in Reinach in the canton of Basel-Landschaft, will be presenting its new product...

Read More
1 2 3 38

Do you have a question? We'd like to hear from you.